Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 331-338

  Chakravarti, Nitin ^a   Kadara, Humam ^a   Yoon, Do Jun ^b   Shay, Jerry W ^b   Myers, Jeffrey N ^a   Lotan, Dafna ^a   Sonenberg, Nahum ^c   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; INITIATION FACTOR; INITIATION FACTOR 4A; INITIATION FACTOR 4E; INITIATION FACTOR 4E BP1; INITIATION FACTOR 4G; INITIATION FACTOR MNK1; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG INHIBITION; EPITHELIUM CELL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOPLAKIA; MOUTH MUCOSA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELLS, CULTURED; CURCUMIN; EUKARYOTIC INITIATION FACTOR-4G; EUKARYOTIC INITIATION FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOUTH MUCOSA; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES;

EID: 77949736603     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0076     Document Type: Article

References (45)

1. von der Haar T, Gross JD, Wagner G, McCarthy JE. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol 2004;11:503-11.
2. Pickering BM, Willis AE. The implications of structured 5′ untranslated regions on translation and disease. Semin Cell Dev Biol 2005; 16:39-47.
3. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001;15:2852-64.
4. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
5. Nathan CA, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999;17:2909-14.
6. Oridate N, Kim HJ, Xu X, Lotan R. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther 2005; 4:318-23.
7. Rojo F, Najera L, Lirola J, et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007;13:81-9.
8. Petricoin EF III, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-40.
9. Assouline S, Culjkovic B, Cocolakis E, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009;114:257-60.
10. Ko SY, Guo H, Barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 2009;15:4336-47.
11. Lin CJ, Sukarieh R, Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther 2009; 8:1606-12.
12. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
13. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006;119:1268-75.
14. LoTempio MM, Veena MS, Steele HL, et al. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:6994-7002.
15. Xu L, Schantz SP, Edelstein D, Sacks PG. A simplified method for the routine culture of normal oral epithelial (NOE) cells from upper aerodigestive tract mucosa. Methods Cell Sci 1996;18:31-9.
16. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027-34.
17. Sacks PG. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996;15:27-51.
18. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981;107:703-10.
19. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981;41:1657-63.
20. Poulin F, Gingras AC, Olsen H, Chevalier S, Sonenberg N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem 1998;273:14002-7.
21. Kadara H, Lacroix L, Lotan D, Lotan R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl) retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther 2007;6: 705-11.
22. Gillenwater A, Zou CP, Zhong M, Lotan R. Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines. Head Neck 2000;22:247-56.
23. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001;92:822-9.
24. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 2009;69:1000-8.
25. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48.
26. Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4Ebinding protein 1. Oncogene 2008;27:1106-13.
27. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999;18:270-9.
28. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-7.
29. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 2004;24:6539-49.
30. von Der Haar T, Ball PD, McCarthy JE. Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5′-Cap by domains of eIF4G. J Biol Chem 2000;275:30551-5.
31. Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E. Over-expression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer 2002;98:181-5.
32. Yu S, Shen G, Khor TO, Kim JH, Kong AN. Curcumin inhibits Akt/ mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008;7:2609-20.
33. Pestova TV, Kolupaeva VG, Lomakin IB, et al. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A 2001; 98:7029-36.
34. Methot N, Song MS, Sonenberg N. A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3. Mol Cell Biol 1996;16:5328-34.
35. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J Biol Chem 1982;257:14806-10.
36. Raught B, Peiretti F, Gingras AC, et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 2004;23:1761-9.
37. Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006;119:757-64.
38. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
39. Kurien BT, Scofield RH. Heat-solubilized curcumin should be considered in clinical trials for increasing bioavailability. Clin Cancer Res 2009;15:747.
40. Kunwar A, Barik A, Pandey R, Priyadarsini KI. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta 2006;1760: 1513-20.
41. Leung MH, Kee TW. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir 2009;25:5773-7.
42. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
43. Wang D, Veena MS, Stevenson K, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res 2008; 14:6228-36.
44. Dujic J, Kippenberger S, Hoffmann S, et al. Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light. J Invest Dermatol 2007;127:1992-2000.
45. Dujic J, Kippenberger S, Ramirez-Bosca A, et al. Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. Int J Cancer 2009;124:1422-8.